Hematologic Malignancies
CanCell Therapeutics focuses its clinical research on relapsed/refractory acute myeloid leukemia, with activity centered on patients whose disease has returned or has not responded adequately to prior treatment.
- Acute myeloid leukemia
- Relapsed disease
- Refractory disease
The company’s research interest is directed toward treatment settings in which hematologic cancer control remains a major clinical need.
Oncology Drug Development
Its clinical portfolio reflects an interest in oncology programs designed to assess safety, tolerability, and anti-leukemic activity in a difficult-to-treat blood cancer population.
- Clinical activity
- Safety and tolerability
- Recommended dose selection
Research activity is concentrated on advancing a candidate therapy for myeloid leukemia through early clinical evaluation.
Leukemia Treatment Innovation
CanCell Therapeutics is engaged in developing therapeutic options for resistant leukemia, with attention to patients who require new approaches after standard treatments have failed.
- Therapy-resistant AML
- Composite complete response
- Antileukemic response
The funded research is positioned within a clinical setting aimed at improving outcomes in advanced blood cancers.
Multinational Clinical Research
The sponsor supports a multicentre research program conducted across several sites and countries, indicating involvement in geographically distributed oncology care and patient access.
- Multicentre trial
- International sites
- Recruiting patients
This research footprint is aligned with clinical development in France and other participating regions in Europe.
